Results 101 to 110 of about 23,348 (143)

Mitochondrial DNA Depletion Syndrome 1 (MTDPS1)—A Novel Cause of Premature Ovarian Insufficiency

Clinical Genetics, Volume 109, Issue 4, Page 784-787, April 2026.
We describe a woman with MNGIE due to a novel homozygous TYMP nonsense variant and propose MNGIE as the cause of her premature ovarian insufficiency—a rarely reported association—highlighting the need to consider mitochondrial disease in unexplained POI, especially in atypical, consanguineous presentations. ABSTRACT Mitochondrial DNA depletion syndrome
Michael Matheou, Helen Turner, Deborah Shears, Fredrik Karpe   +3 more
wiley   +1 more source

Rosiglitazone and Pioglitazone Alter Aromatase Kinetic Properties in Human Granulosa Cells

PPAR Research, 2011
We have previously reported that, in human granulosa cells, thiazolidinediones rosiglitazone and pioglitazone inhibit estrogen synthesis by interfering with androgen binding to aromatase, without an effect on aromatase mRNA or protein expression.
Takako Araki, Miroslava Varadinova, Michael Goldman, Zev Rosenwaks, Leonid Poretsky, Donna Seto-Young   +5 more
doaj   +1 more source

Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective

Cost Effectiveness and Resource Allocation, 2009
Background The aim of this study was to project health-economic outcomes relevant to the German setting for the addition of pioglitazone to existing treatment regimens in patients with type 2 diabetes, evidence of macrovascular disease and at high risk ...
Massi-Benedetti Massimo, Erny-Albrecht Katrina M, Goodall Gordon, Scherbaum Werner A, Erdmann Erland, Valentine William J   +5 more
doaj   +1 more source

Effects of the peroxisome proliferator-activated receptor (PPAR)-γ agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals [PDF]

, 2018
Aims/hypothesis: Glitazones are powerful insulin sensitisers prescribed for the treatment of type 2 diabetes. Their use is, however, associated with fluid retention and an increased risk of congestive heart failure.
Burnier, M., Deleaval, P., Jornayvaz, F., Maillard, M., Nussberger, J., Pechere-Bertschi, A., Vinciguerra, M., Zanchi, A.   +7 more
core  

Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double‐blind, placebo‐controlled trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 2978-2987, April 2026.
Abstract Aims The precise mechanism of sodium glucose co‐transporter 2 (SGLT2) inhibitor on reno‐protective effect has been still unclear. In this study, we hypothesised that SGLT2 inhibitor prevents diabetic kidney disease via reduction of hypoxia‐induced factors.
Hisashi Makino, Masato Kasahara, Ryuzo Takashima, Shu Kasama, Naoki Ozu, Hyohun Park, Qingxing Chen, Kazuhiko Tsuruya, Mayu Tochiya, Yoko Omura‐Ohata, Tamiko Tamanaha, Michio Noguchi, Takeshi Aiba, Fumiki Yoshihara, Kiminori Hosoda   +14 more
wiley   +1 more source

Cardiovascular Outcomes in Patients With Previous Myocardial Infarction and Mild Diabetes Mellitus Following Treatment With Pioglitazone

EClinicalMedicine, 2018
Background: Secondary prevention in patients with myocardial infarction (MI) is critically important to prevent ischaemic heart failure and reduce social burden. Pioglitazone improves vascular dysfunction and prevents coronary atherosclerosis, mainly via
Masanori Asakura, Jiyoong Kim, Hiroshi Asanuma, Yasuharu Nakama, Kengo Tsukahara, Yorihiko Higashino, Tetsuya Ishikawa, Shinji Koba, Mitsuru Tsujimoto, Hideo Himeno, Yasuyuki Maruyama, Takanori Ookusa, Shunichi Yoda, Hiroshi Suzuki, Shinji Okubo, Makoto Shimizu, Yuji Hashimoto, Kazuo Satake, Susumu Fujino, Hiroyasu Uzui, Yoshiyuki Nagai, Tohru Kohno, Sumio Mizuno, Makoto Nakahama, Hounin Kanaya, Toyoaki Murohara, Kazuki Fukui, Hiroyuki Takase, Nobuyuki Ohte, Takaaki Shiono, Masatake Fukunami, Tsutomu Endo, Reimin Sawada, Kenshi Fujii, Motoshi Takeuchi, Shuntaro Ikeda, Koichi Mizuno, Masaaki Uematsu, Taku Matsubara, Shoji Yano, Jun Takahashi, Kousei Ueda, Yoshihiko Kinoshita, Koichi Tamita, Hideki Hayashi, Toshimitsu Hamasaki, Masafumi Kitakaze   +46 more
doaj   +1 more source

Effect of Hormone Replacement Therapy on Liver and Cardiometabolic Outcomes in Peri‐Menopausal MASLD

Liver International, Volume 46, Issue 4, April 2026.
ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. Menopause is associated with increased hepatic fat deposition and thus metabolic dysfunction, contributing to heightened risk of progressive liver and cardiovascular disease.
Alex E. Henney, Jo Wilson, David R. Riley, Uazman Alam, Daniel J. Cuthbertson   +4 more
wiley   +1 more source

Effects of Resveratrol on pharmacokinetics and pharmacodynamics of Pioglitazone in Diabetic rats [PDF]

Perspectives In Medical Research, 2017
Introduction: Diabetes is a group of metabolic disorders characterized by a chronic hyperglycaemic condition resulting from insufficient action of insulin.
Raju Devde1 , Narasimha Reddy Y2 , Sravanthi K3 , Abid Ali4 , Imran Khan5
doaj  

Pioglitazone: Indian perspective

Indian Journal of Endocrinology and Metabolism, 2011
Pioglitazone was approved in 1999 as an adjunct to exercise and diet to improve glycemic control in adults with type 2 diabetes mellitus, primarily by reducing insulin resistance.
Rishi Shukla, Sanjay Kalra
doaj  

Identification of Potential Therapeutic Targets in the Liver of Pioglitazone-Treated Type 2 Diabetes Sprague-Dawley Rats via Expression Profile Chip and iTRAQ Assay

Journal of Diabetes Research, 2018
The aim of the present study was to identify key antidiabetic nodes in the livers of pioglitazone-treated type 2 diabetes mellitus Sprague-Dawley rats by transcriptomic and proteomic analysis.
Zhong-Xia Lu, Wen-Jun Xu, Yang-Sheng Wu, Chang-Yu Li, Yi-Tao Chen   +4 more
doaj   +1 more source